Shopping Cart 0
Cart Subtotal
USD 0

Curevac AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Curevac AG (Curevac), formerly CureVac GmbH is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA technology platforms include RNArt, RNActive, RNAntibody, and RNAdjuvant. Curevac's RNActive technology is used to develop treatments against cancer and prophylactic vaccines for infectious diseases. The company's RNAdjuvant technology is used to enhance the immune response of other vaccines. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. It operates through pharmaceutical companies and research institutes. CureVac is headquartered in Tubingen, Germany.

Curevac AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Curevac AG, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

CureVac to Raise USD76 Million in Venture Financing 10

CureVac Raises USD 105 Million In Series D Financing 11

Partnerships 12

Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12

Eli Lilly and CureVac Enter into Partnership 13

International AIDS Vaccine Partners with CureVac 14

CureVac to Enter into Development Agreement with Bill & Melinda Gates 15

Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16

Licensing Agreements 17

CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17

Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20

Equity Offering 21

CureVac Raises Additional USD29.5 Million in Private Placement 21

CureVac Raises USD110 Million in Private Placement of Shares 22

Curevac AG-Key Competitors 23

Curevac AG-Key Employees 24

Curevac AG-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Strategy And Business Planning 26

Jan 10, 2018: CureVac Highlights Key 2018 Corporate Milestones and Outlook 26

Oct 30, 2017: CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics 27

Corporate Communications 28

May 08, 2018: CureVac Announces New Management Structure 28

Government and Public Interest 29

Feb 13, 2018: CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria 29

Product News 30

Oct 23, 2017: Publication in npj Vaccines Demonstrates CureVac's RNActive Vaccine is Superior to Licensed Vaccines 30

Clinical Trials 31

Oct 27, 2017: CureVac Initiates Phase I Clinical Trial of RNAdjuvant Candidate as Intratumoral Therapy for Solid Tumors 31

Other Significant Developments 32

Jun 26, 2017: CureVac Expands GMP Production Capacities for RNA Products 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Curevac AG, Pharmaceuticals & Healthcare, Key Facts 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Deals By Therapy Area, 2012 to YTD 2018 8

Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CureVac to Raise USD76 Million in Venture Financing 10

CureVac Raises USD 105 Million In Series D Financing 11

Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12

Eli Lilly and CureVac Enter into Partnership 13

International AIDS Vaccine Partners with CureVac 14

CureVac to Enter into Development Agreement with Bill & Melinda Gates 15

Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16

CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17

Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20

CureVac Raises Additional USD29.5 Million in Private Placement 21

CureVac Raises USD110 Million in Private Placement of Shares 22

Curevac AG, Key Competitors 23

Curevac AG, Key Employees 24

Curevac AG, Other Locations 25

Curevac AG, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Curevac AG (Curevac), formerly CureVac GmbH is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA technology platforms include RNArt, RNActive, RNAntibody, and RNAdjuvant. Curevac's RNActive technology is used to develop treatments against cancer and prophylactic vaccines for infectious diseases. The company's RNAdjuvant technology is used to enhance the immune response of other vaccines. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. It operates through pharmaceutical companies and research institutes. CureVac is headquartered in Tubingen, Germany.

Curevac AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Curevac AG, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

CureVac to Raise USD76 Million in Venture Financing 10

CureVac Raises USD 105 Million In Series D Financing 11

Partnerships 12

Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12

Eli Lilly and CureVac Enter into Partnership 13

International AIDS Vaccine Partners with CureVac 14

CureVac to Enter into Development Agreement with Bill & Melinda Gates 15

Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16

Licensing Agreements 17

CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17

Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20

Equity Offering 21

CureVac Raises Additional USD29.5 Million in Private Placement 21

CureVac Raises USD110 Million in Private Placement of Shares 22

Curevac AG-Key Competitors 23

Curevac AG-Key Employees 24

Curevac AG-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Strategy And Business Planning 26

Jan 10, 2018: CureVac Highlights Key 2018 Corporate Milestones and Outlook 26

Oct 30, 2017: CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics 27

Corporate Communications 28

May 08, 2018: CureVac Announces New Management Structure 28

Government and Public Interest 29

Feb 13, 2018: CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria 29

Product News 30

Oct 23, 2017: Publication in npj Vaccines Demonstrates CureVac's RNActive Vaccine is Superior to Licensed Vaccines 30

Clinical Trials 31

Oct 27, 2017: CureVac Initiates Phase I Clinical Trial of RNAdjuvant Candidate as Intratumoral Therapy for Solid Tumors 31

Other Significant Developments 32

Jun 26, 2017: CureVac Expands GMP Production Capacities for RNA Products 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Curevac AG, Pharmaceuticals & Healthcare, Key Facts 2

Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curevac AG, Deals By Therapy Area, 2012 to YTD 2018 8

Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CureVac to Raise USD76 Million in Venture Financing 10

CureVac Raises USD 105 Million In Series D Financing 11

Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12

Eli Lilly and CureVac Enter into Partnership 13

International AIDS Vaccine Partners with CureVac 14

CureVac to Enter into Development Agreement with Bill & Melinda Gates 15

Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16

CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17

Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20

CureVac Raises Additional USD29.5 Million in Private Placement 21

CureVac Raises USD110 Million in Private Placement of Shares 22

Curevac AG, Key Competitors 23

Curevac AG, Key Employees 24

Curevac AG, Other Locations 25

Curevac AG, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS